Joan Merrill, M.D., is a recipient of the 2018 ACR Master designation, one of the highest honors members can receive.
The trio of scientists assumed their new positions at the foundation Nov. 1, bringing the total number of OMRF senior scientists to 49.
Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.
OMRF researchers have broken new ground in understanding how the lymphatic system works.
The 11th annual Putnam City Cancer Classic will take place on Nov. 3 at Wheeler Park on the Oklahoma River.
OMRF’s Sarcoidosis Unit, which launched in January, is the only one of its kind in the state.